Our National Vaccine and Therapeutics Lab turns vaccine and drug candidates into manufacturable products on a large scale.
Competing globally in vaccine and drug development
After a successful pilot facility brought about in the early stages of the COVID-19 pandemic, the $23.1 million, multi-purpose facility allows biomedical manufacturing researchers and industry partners to safely scale-up vaccine candidates.
Having received funding from both the Federal and Victorian Governments, the National Vaccine and Therapeutics Lab is the missing link in Australia's biomedical science sector, giving local companies the chance to compete globally and avoid the high costs and waiting lists of producing vaccines offshore.
The state-of-the-art lab also aims to help Small to Medium Enterprises (SMEs) bridge the gap between benchtop lab research and commercial scale (known as the 'valley of death').
The National Vaccine and Therapeutics Lab’s accreditation
The lab is able to produce a variety of biologics, including recombinant proteins and peptides, and viral products. It also develops antibodies, antibody conjugates such as theranostics, protein subunit vaccines, viral vector vaccines and virus-like particles.
The lab is designed in accordance with the Australian Therapeutic Goods Administration's licensing. To help support the facility, we're also building a Good Manufacturing Practice-compliant Quality Control laboratory to support the analytics and stability trials required for biologic release.
As a major boost to Australian translational research capacity and advanced manufacturing in biotechnology, the new facility has been designed to provide for future accreditation with the US Food and Drug Administration (FDA) and the European Medicines Agency, enabling local biotech companies access to the overseas market.
Playing a significant role in Australia's biosafety network, the lab forms part of the broader National Biologics Facility, with branches at the University of Queensland, University of Technology Sydney and CSIRO. It’s funded under the National Collaborative Research Infrastructure Strategy (NCRIS) and administered by TIA.
The National Vaccine and Therapeutics Lab was opened 2022 by Federal Minister for Industry and Science the Hon. Ed Husic.
The facility is available to companies and researchers around Australia. We encourage biotech companies to get in touch.
Our National Vaccine and Therapeutics Lab turns vaccine and drug candidates into manufacturable products on a large scale.
Competing globally in vaccine and drug development
After a successful pilot facility brought about in the early stages of the COVID-19 pandemic, the $23.1 million, multi-purpose facility allows biomedical manufacturing researchers and industry partners to safely scale-up vaccine candidates.
Having received funding from both the Federal and Victorian Governments, the National Vaccine and Therapeutics Lab is the missing link in Australia's biomedical science sector, giving local companies the chance to compete globally and avoid the high costs and waiting lists of producing vaccines offshore.
The state-of-the-art lab also aims to help Small to Medium Enterprises (SMEs) bridge the gap between benchtop lab research and commercial scale (known as the 'valley of death').
The National Vaccine and Therapeutics Lab’s accreditation
The lab is able to produce a variety of biologics, including recombinant proteins and peptides, and viral products. It also develops antibodies, antibody conjugates such as theranostics, protein subunit vaccines, viral vector vaccines and virus-like particles.
The lab is designed in accordance with the Australian Therapeutic Goods Administration's licensing. To help support the facility, we're also building a Good Manufacturing Practice-compliant Quality Control laboratory to support the analytics and stability trials required for biologic release.
As a major boost to Australian translational research capacity and advanced manufacturing in biotechnology, the new facility has been designed to provide for future accreditation with the US Food and Drug Administration (FDA) and the European Medicines Agency, enabling local biotech companies access to the overseas market.
Playing a significant role in Australia's biosafety network, the lab forms part of the broader National Biologics Facility, with branches at the University of Queensland, University of Technology Sydney and CSIRO. It’s funded under the National Collaborative Research Infrastructure Strategy (NCRIS) and administered by TIA.
The National Vaccine and Therapeutics Lab was opened 2022 by Federal Minister for Industry and Science the Hon. Ed Husic.
The facility is available to companies and researchers around Australia. We encourage biotech companies to get in touch.